Of note, PU.1 expression is not uniform across primary myelomas or myeloma cell lines, suggesting the potential for significant variation in transcriptional input from IRF4 in plasma cell malignancies, which will be important to explore in future. The gene discussed is IRF4; the disease is plasma cell myeloma.